Thu, 22 Apr 2021 12:00:00 EDT Continuous Glucose Monitoring Initiation at Hospital Discharge Conditions: Type 1 Diabetes; Type2 Diabetes; Hyperglycemia; Hypoglycemia; Hypoglycemia Unawareness Intervention: Device: CGM4Home Sponsor: Washington University School of Medicine Recruiting
Thu, 22 Apr 2021 12:00:00 EDT Dairy Products With Reduced Sugar and Blood Glucose Conditions: Blood Glucose, High; Metabolic Disease; Overweight and Obesity Intervention: Other: Food Sponsor: Mount Saint Vincent University Not yet recruiting
Thu, 22 Apr 2021 12:00:00 EDT Ketone Esters in T2DM Condition: Type 2 Diabetes Interventions: Dietary Supplement: Ketone monoesters; Dietary Supplement: Placebo Sponsors: University of Portsmouth; Portsmouth Hospitals NHS Trust Not yet recruiting
Thu, 22 Apr 2021 12:00:00 EDT Prevention of Pre-eclampsia Using Metformin: a Randomized Control Trial Conditions: Preeclampsia; Preeclampsia Severe; High Risk Pregnancy; Eclampsia Intervention: Drug: Metformin Sponsors: Hamad Medical Corporation; Sidra Medical and Research Center Not yet recruiting
Wed, 21 Apr 2021 12:00:00 EDT Fast Advanced Closed-Loop Therapy Condition: Type 1 Diabetes Interventions: Drug: Fiasp; Drug: Novorapid Sponsors: University of Ljubljana, Faculty of Medicine; Medical University of Graz Department of Pediatrics and Adolescent Medicine, Graz, Austria; UMC Ljubljana University Children's Hospital Ljubljana Recruiting
FDA (Food and Drug Administration) press releases. FDA makes sure of the safety of all medicines which can be injected, breathed in, rubbed in and swallowed, in the United States of America.
Fri, 16 Apr 2021 15:31:27 EDT FDA Approves First Immunotherapy for Initial Treatment of Gastric Cancer Today, the FDA approved Opdivo (nivolumab), in combination with certain types of chemotherapy, for the initial treatment of patients with advanced or metastatic gastric cancer, gastroesophageal junction cancer and esophageal adenocarcinoma.
